MarketFriction

Mangalam Drugs and Organics Ltd

NSE MANGALAM · BSE 532637 · Pharmaceuticals
₹29.15 -5.17%
NSE close2026-10-01
52 week range22.80 - 73.94
Market cap₹50.3 Cr.
ASM long-term Price band 10% Delivery 69.3%

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Standalone, Rs crore
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales81.5697.34102.2476.5379.9488.7172.7857.2149.5458.3867.2957.12
Expenses79.3790.3690.5468.3471.2579.9462.8861.8652.3759.9672.6556.22
Operating Profit2.196.9811.708.198.698.779.90-4.65-2.83-1.58-5.360.90
OPM %2.69%7.17%11.44%10.70%10.87%9.89%13.60%-8.13%-5.71%-2.71%-7.97%1.58%
Other Income0.030.000.050.020.140.130.470.140.030.220.090.11
Interest3.243.313.953.753.673.494.034.045.034.053.083.68
Depreciation3.733.623.863.873.973.934.614.384.534.374.563.99
Profit before tax-4.750.053.940.591.191.481.73-12.93-12.36-9.78-12.91-6.66
Tax %-25.05%-920.00%9.90%-355.93%-125.21%5.41%90.75%6.19%-41.42%0.00%1.16%13.36%
Net Profit-3.560.503.552.682.691.400.15-13.73-7.25-9.78-13.06-7.55
EPS in Rs-2.250.322.241.691.700.880.09-8.67-4.58-6.18-8.25-4.77
Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales295299269228282380451372369318232232
Expenses257252222218259327402347351282247241
Operating Profit38474710245349261736-15-9
OPM %13%16%17%4.3%8%14%11%7%4.7%11%-6%-3.8%
Other Income0-01015000010
Interest910129109111314151616
Depreciation457789101115161817
Profit before tax243129-6640282-115-48-42
Tax %33%29%32%40%-32%29%29%43%-18%-39%-9%
Net Profit162220-8828201-97-44-38
EPS in Rs11.1514.0812.57-5.075.2117.6712.420.80-5.724.37-27.68-23.78
Dividend Payout %0%0%4%0%0%0%0%0%0%0%0%
10 Years5 Years3 YearsTTM1 YearLast Year
Compounded Sales Growth-2%-9%-15%-22%
Compounded Profit Growth%%%-297%
Stock Price CAGR-15%-27%-33%-58%
Return on Equity4%-4%-11%-35%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital131416161616161616161616
Reserves16477088808811513513612713387
Borrowings78606669655270888910796105
Other Liabilities633838545075649011710811499
Total Liabilities170160190227211231264328358357359308
Fixed Assets535493102103101118135142147156152
CWIP050001669830
Investments002000000000
Other Assets11710095125107128140188206202201156
Total Assets170160190227211231264328358357359308
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity14224325223128263812434
Cash from Investing Activity-4-11-39-16-9-7-31-27-22-18-19-12
Cash from Financing Activity-10-11-3-9-11-2333-176-226
Net Cash Flow1-00-010-11-1-02-2
Free Cash Flow1011391224-4-216-623-8
CFO/OP69%68%107%66%223%129%69%70%148%71%119%-30%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days733745612852523846284563
Inventory Days134856913217512185139200185303239
Days Payable128373882771066365139124199160
Cash Conversion Cycle798575111126677411210788148142
Working Capital Days2632193121102343381813-54
ROCE %16%29%31%25%2%11%27%18%6%1%8%-14%
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters50.31%50.31%50.31%50.31%50.30%50.30%50.30%50.30%50.30%35.64%35.65%35.65%
FIIs0.10%0.10%0.26%0.21%0.11%0.11%0.47%0.53%0.11%0.13%0.32%0.11%
Public49.59%49.59%49.42%49.47%49.58%49.58%49.23%49.16%49.57%64.22%64.03%64.24%
No. of Shareholders17,97818,61019,17319,31219,50819,67919,69719,72819,88121,22725,14024,465

Fundamentals

Market Cap₹ 50.3 Cr.
Current Price₹ 31.8
Book Value₹ 65.3
ROCE-14.0 %
ROE-34.8 %
Dividend Yield0.00 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)-22%
Compounded Profit Growth (TTM)-297%
Standalone figures.
Valuation
Market capRs 46 Cr
Enterprise valueRs 151 Cr
Price to book0.45x
Price to sales0.20x
EV / sales0.65x
Price to cash flow11.09x
Earnings yield-81.61%
P/E, 3-year average16.99x
P/B, 3-year average0.91x
P/E, 5-year average49.13x
P/B, 5-year average0.98x
Profitability
Operating margin (excl. other income)-6.33%
Operating margin (incl. other income)-6.00%
EBITDA margin-3.62%
Pre-tax margin-17.95%
Net profit margin-16.20%
Net margin, latest quarter-13.22%
ROE-34.77%
ROCE-14.01%
ROA-13.13%
ROE, 3-year average-12.06%
ROCE, 3-year average-1.59%
ROA, 3-year average-4.58%
ROE, 5-year average-4.27%
ROCE, 5-year average3.86%
ROA, 5-year average-1.34%
ROIC (approx.)-11.35%
Tax rate8.69%
Other income / net worth0.74%
Growth
Sales growth (latest year)-27.06%
Profit growth (latest year)-733.09%
Sales CAGR, 3 years-14.57%
Sales CAGR, 5 years-9.39%
Sales growth QoQ-15.11%
Sales growth YoY (latest quarter)-0.16%
Per share
EPS (TTM)Rs -23.79
EPS (latest quarter)Rs -4.77
EPS, 3-year averageRs -0.67
EPS, 5-year averageRs 2.97
Book value per shareRs 65.30
Sales per shareRs 146.85
Cash flow per shareRs 2.63
Free cash flow per shareRs -5.06
Efficiency
Asset turnover0.75x
Fixed asset turnover1.53x
Inventory turnover1.53x
Inventory days239 days
Debtor days63 days
Debtors turnover5.76x
Creditor days160 days
Cash conversion cycle142 days
Working capital days-54 days
Leverage
Total debtRs 105 Cr
Cash and bankRs 1 Cr
Net debtRs 105 Cr
Debt to equity1.02x
Interest coverage-1.63x
Owners' fund to total sources33.53%
Debt to assets34.23%
Cash flow
Cash from Operating Activity (latest year)Rs 4 Cr
Cash from Investing Activity (latest year)Rs -12 Cr
Cash from Financing Activity (latest year)Rs 6 Cr
Net Cash Flow (latest year)Rs -2 Cr
Free cash flow (latest year)Rs -8 Cr
FCFE (approx.: FCF + change in debt)Rs 1 Cr
Sales to cash flow55.80x
Statement figures
Net sales (TTM)Rs 232 Cr
Net sales (latest year)Rs 232 Cr
Sales (latest quarter)Rs 57 Cr
Operating profit excl. other income (latest year)Rs -15 Cr
Operating profit (latest quarter)Rs 1 Cr
Other income (TTM)Rs 0 Cr
EBITDA (TTM)Rs -8 Cr
PBDT (TTM)Rs -24 Cr
Profit before tax (TTM)Rs -42 Cr
Tax (latest year)Rs -4 Cr
Net profit (TTM)Rs -38 Cr
Net profit (latest year)Rs -44 Cr
Net profit (latest quarter)Rs -8 Cr
Depreciation (TTM)Rs 17 Cr
Depreciation (latest quarter)Rs 4 Cr
Interest (TTM)Rs 16 Cr
Cost of goods sold (latest year)Rs 157 Cr
Total expenditure (latest year)Rs 247 Cr
Total income (latest year)Rs 233 Cr
Share capitalRs 16 Cr
ReservesRs 87 Cr
Shareholders' fundsRs 103 Cr
Total assetsRs 308 Cr
Net blockRs 152 Cr
InvestmentsRs 0 Cr
ReceivablesRs 40 Cr
InventoryRs 103 Cr
Other liabilitiesRs 99 Cr
Shares outstanding (crore)1.58
Ownership
Promoter holding35.65% (-14.65 in a year)
Computed by MarketFriction from the standalone statements. Returns use average balances.
P/B 0.45 is at the 8th percentile (median 1.16).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
PeriodMANGALAMNifty 50Difference
1 week-7.9%-2.8% -5.1 pts
1 month-2.4%-6.8% +4.4 pts
3 months+3.8%-7.6% +11.4 pts
6 months+7.4%+0.4% +7.0 pts
1 year-60.6%-9.9% -50.7 pts
2 years-77.1%-13.6% -63.6 pts
3 years-71.9%+14.2% -86.1 pts
5 years-80.2%+27.9% -108.1 pts

Red flags

F-score 3 of 8
explainReceivables outrunning sales Receivables grew 3% vs sales -27% in 2026
lookOn NSE surveillance On NSE surveillance: ASM long-term
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Latest quarter

Jun 2026
Sales ₹57 Cr -0.2% vs Jun 2025. Net loss ₹8 Cr.

Activity

Compare
CompanyMcap (Cr)P/EROCE
Sun Pharmaceutical Industries Ltd447,47635.420.5 %
Divis Laboratories Ltd250,36384.022.0 %
Torrent Pharmaceuticals Ltd186,15283.415.2 %
Zydus Lifesciences Ltd119,75024.621.1 %
Cipla Ltd111,43031.115.5 %
Laurus Labs Ltd106,92897.817.8 %
Mankind Pharma Ltd105,12049.313.5 %
Dr Reddys Laboratories Ltd104,49432.413.0 %
Aurobindo Pharma Ltd97,68225.812.9 %
Lupin Ltd93,84015.829.9 %
Glenmark Pharmaceuticals Ltd68,90522.139.8 %
Alkem Laboratories Ltd62,77227.621.2 %
Biocon Ltd61,43984.53.61 %
Abbott India Ltd57,94935.944.8 %
Gland Pharma Ltd49,33343.115.1 %
No bulk or block deals on record.
Ex-dateActionFactor
2018-09-17 Annual General Meeting
2017-12-21 Interim Dividend Re 0.50 Per Share
2017-09-18 Annual General Meeting
2016-09-22 Annual General Meeting (Book Closure Dates Revised)
2015-08-26 Annual General Meeting
2014-09-18Annual General Meeting
2013-09-17Annual General Meeting
2012-09-17Annual General Meeting
2011-09-20Annual General Meeting
2010-09-21Annual General Meeting
2009-09-17Annual General Meeting
2008-09-18Annual General Meeting
2007-09-18Agm
2006-09-19Agm/Div-Re0.20 Per Share
DateTypeWhat it says
2026-10-01Shareholder meetingNotice of Postal Ballot
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
EPS in the scrip is zero (4 trailing quarters)Long Term Additional Surveillance Measure (Long Term ASM): stage 1
Data: NSE and BSE daily reports, company filings. Numbers only, not investment advice, not a SEBI-registered research service.Updated 2026-10-03